The purpose of the IBC is to ensure that the NIH Guidelines for Research Involving Recombinant DNA or Synthetic Nucleic Acid Molecules are adhered to at FIU. The purpose of the NIH Guidelines is to specify the practices for constructing and handling: (i) recombinant nucleic acid molecules, (ii) synthetic nucleic acid molecules, including those that are chemically or otherwise modified but can base pair with naturally occurring nucleic acid molecules, and (iii) cells, organisms, and viruses containing such molecules. See the section Definition of Recombinant DNA Molecules for further detail.
FIU requires that all use of recombinant DNA and/or Synthetic Nucleic Acid molecules at the University be registered with the Institutional Biosafety Committee.
This site contains the necessary tools and information to assist investigators during the IBC protocol submission and review process. You can find them on the left navigation menu including Obtaining IBC Approval which provides step by step instructions on preparing your submission, Policies & Procedures which contains helpful resources on conducting research with Recombinant DNA or Synthetic Nucleic Acid, and IBC FAQs which contains answers to commonly asked questions.
The Office of Research Integrity (ORI) is responsible for the ethical and regulatory oversight of research at Florida International University that involves Recombinant DNA. ORI supports and oversees the work of the Institutional Biosafety Committee (IBC).
The IBC Chairperson is Kathleen Rein and can be reached at: (305) 348-6682